<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885374</url>
  </required_header>
  <id_info>
    <org_study_id>ALS-2021-CARE-TCM</org_study_id>
    <nct_id>NCT04885374</nct_id>
  </id_info>
  <brief_title>China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine</brief_title>
  <acronym>CARE-TCM</acronym>
  <official_title>China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongzhimen Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dongzhimen Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center registration study of clinical characteristics of amyotrophic lateral&#xD;
      sclerosis (ALS) patients with traditional Chinese medicine (TCM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CARE-TCM is a prospective, multi-center, patient registry study. Eligible ALS patients&#xD;
      with TCM treatments will be enrolled in the registry. After enrollment, this research&#xD;
      collects the individual characteristics of patients' status. Longitudinal follow-up data are&#xD;
      collected from both patients (primary caregivers) and their treating neurologists every 3&#xD;
      months for 5 years. The aims of the CARE-TCM are to: 1) explore the general characteristics&#xD;
      of ALS patients with TCM and; 2) assess the effectiveness and safety of various TCMs on ALS&#xD;
      based on nationwide registry outcome collecting process.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Effective Survival</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>The time from disease onset to death, tracheostomy, or permanent assisted ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>Death owing to any causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Disease Progression</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>(48-total ALSFRS-R)/symptom duration (months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Forced Vital Capacity (FVC) Decline</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>The slope of decline of forced vital capacity (FVC) to assess the respiratory function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Body Mass Index (BMI) Decline</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>The slope of decline of body mass index (BMI) to assess the disease progression.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Amyotrophic lateral sclerosis patients</arm_group_label>
    <description>Amyotrophic lateral sclerosis patients with traditional Chinese medicine</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who meet the criteria will be enrolled from multi-centers in China.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years and older.&#xD;
&#xD;
          -  Patients with possible, laboratory supported probable, probable, or definite ALS&#xD;
             according to the revised El Escorial criteria.&#xD;
&#xD;
          -  ALS patients treated with traditional Chinese medicine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Gao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongzhimen Hospital, Beijing University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Gao, MD, PhD</last_name>
    <phone>+86-10-84013209</phone>
    <email>gaoying973@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dongzhimen Hospital, Beijing University of Chinese Medicine</name>
      <address>
        <city>Beijing</city>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Gao, MD, PhD</last_name>
      <phone>+86-10-84013209</phone>
      <email>gaoying973@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 8, 2021</study_first_submitted>
  <study_first_submitted_qc>May 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 8, 2021</last_update_submitted>
  <last_update_submitted_qc>May 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dongzhimen Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Ying Gao</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

